Biocon Receives Health Canada Approval for Yesintek Autoinjector Pen
Biocon's Canadian subsidiary has received Health Canada's Notice of Compliance for its Yesintek (ustekinumab) autoinjector in 45 mg and 90 mg strengths. This approval adds a new delivery option for treating moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The autoinjector offers a treatment format not available from the originator product in Canada, supporting personalized care. This expands Biocon's immunology portfolio and reinforces its commitment to affordable biosimilar medicines globally.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (58/100). Lens Score 39/100.
Outlets measured: thefinancialexpress, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 29 Jul, 04:47 am. Other outlets followed.
- 1